Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and Pembrolizumab in Higher Risk MDS
NCT03094637Phase 2Unknown
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2017
- Primary completion
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Status: unknown.
02
Drugs
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03094637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03094637.